Starpharma Holdings Overview

  • Founded
  • 1996
Founded
  • Status
  • Public
  • Employees
  • 32
Employees
  • Stock Symbol
  • SPL
Stock Symbol
  • Share Price
  • $0.55
  • (As of Friday Closing)

Starpharma Holdings General Information

Description

Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis, and as a condom coating and VIRALEZE an antiviral nasal spray.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Personal Products
Drug Discovery
Stock Exchange
ASX
Primary Office
  • PO Box 2022
  • 75 Commercial Road
  • Preston, Victoria 3072
  • Australia
+61 (03) 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Starpharma Holdings Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.55 $0.53 $0.50 - $1.42 $222M 407M 413K

Starpharma Holdings Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 30-Jun-2021 FY 2020 30-Jun-2020 FY 2019 30-Jun-2019
EV 242,049 411,548 268,425 322,696
Revenue 1,340 4,041 1,180
EBITDA (14,278) (9,572) (10,735)
Net Income (14,711) (9,832) (10,192)
Total Assets 55,026 26,851 34,218
Total Debt 877 1,082 18
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Starpharma Holdings Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Starpharma Holdings‘s full profile, request access.

Request a free trial

Starpharma Holdings Patents

Starpharma Holdings Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3120881-A1 Dendrimer for therapy and imaging Pending 29-Nov-2018 0000000000
EP-3886912-A1 Dendrimer for therapy and imaging Pending 29-Nov-2018 0000000000
AU-2019390489-A1 Dendrimer for therapy and imaging Pending 29-Nov-2018 0000000000
CA-3119993-A1 Therapeutic dendrimer Pending 20-Nov-2018 0000000000
AU-2019383466-A1 Therapeutic dendrimer Pending 20-Nov-2018 C07D491/22
To view Starpharma Holdings’s complete patent history, request access »

Starpharma Holdings Executive Team (3)

Name Title Board Seat Contact Info
Jackie Fairley Chief Executive Officer & Executive Director
Nigel Baade Chief Financial Officer & Company Secretary
John Raff Ph.D Deputy Chairman
To view Starpharma Holdings’s complete executive team members history, request access »

Starpharma Holdings Board Members (1)

Name Representing Role Since
00000 00000000 Starpharma Holdings Board Member 000 0000
To view Starpharma Holdings’s complete board members history, request access »

Starpharma Holdings Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Starpharma Holdings Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Starpharma Holdings‘s full profile, request access.

Request a free trial